Corcept医疗（CORT）在盘后交易中股价大涨18.34%，报110.0美元/股，成交额达到874.61万美元，引发市场广泛关注。
消息面上，公司公布了第二季度财报，业绩表现大幅超出市场预期。每股收益（EPS）为0.36美元，远超分析师一致预期的0.00美元，同比增长24.14%；营收达到2.56亿美元，同样超出分析师预期的2.20亿美元约16.4%。此前一季度公司曾录得每股亏损0.30美元，本季度实现强劲反转，主要得益于核心产品Korlym及新获批药物Lifyorli™（Relacorilant）的商业化推进。
此外，公司已于6月重新提交了Relacorilant用于治疗库欣综合征的新药申请，多条在研管线进展顺利，进一步提振了市场信心。同时，Canaccord Genuity也将Corcept医疗的目标价从135美元上调至150美元，显示出机构对公司未来前景的看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.